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Estrogen Receptor-α Quantification in Breast Cancer:
Concordance Between Immunohistochemical Assays
and mRNA-In Situ Hybridization for ESR1 Gene
Christian Thomsen, MD,* Søren Nielsen, HT, CT,*† Boye S. Nielsen, PhD,‡
Sine H. Pedersen, MD,* and Mogens Vyberg, MD†§
Abstract: Immunohistochemical (IHC) quantification of estrogen
receptor-α (ER) is used for assessment of treatment regimen in
breast cancer. Different ER IHC assays may produce diverging
results, because of different antibody clones, protocols, and
stainer platforms. Objective tissue-based techniques to assess
sensitivity and specificity of IHC assays are therefore needed. We
tested the usability of ER mRNA-in situ hybridization (mRNA-
ISH) in comparison with assays based on clones SP1 and 6F11.
We selected 56 archival specimens according to their reported
ER IHC positivity, representing a wide spectrum from negative
to strongly positive cases. The specimens were used to prepare 4
TMAs with 112 cores. Serial sections of each TMA were stained
for ER and pan-cytokeratin (PCK) by IHC and ESR1 (ER gene)
by mRNA-ISH. Digital image analysis (DIA) was used to de-
termine ER IHC H-score. ESR1 mRNA-ISH was scored both
manually and by DIA. DIA showed a nonlinear correlation
between IHC and ESR1 mRNA-ISH with R2-values of 0.80 and
0.78 for the ER antibody clones SP1 and 6F11, respectively.
Comparison of manual mRNA-ISH scoring categories and SP1
and 6F11 IHC H-scores showed a highly significant relationship
(P< 0.001). In conclusion, the study showed good correlation
between mRNA-ISH and IHC, suggesting that mRNA-ISH
can be a valuable tool in the assessment of the sensitivity and
specificity of ER IHC assays.
Key Words: estrogen receptor, immunohistochemistry, mRNA
in situ hybridization, specificity
(Appl Immunohistochem Mol Morphol 2020;28:347–353)
BACKGROUND
The use of immunohistochemical (IHC) detection of
biomarkers is fundamental in the field of surgical pathol-
ogy, and reliable results of the analysis are essential in order
to make the right diagnosis and to offer the most efficient
treatment.1 One example of this is the assessment of es-
trogen receptor α (ER) expression in breast cancer, which is
of both prognostic and predictive value.2 According to in-
ternational guidelines, tumors should be reported as ER-
positive even with a weak immunoreactivity in ≥ 1% of the
tumor cells, as this predicts responsiveness to endocrine
therapy.3 This places strong demands on the performance
of the ER assays in terms of sensitivity and specificity.
Nordic immunohistochemical Quality Control (Nor-
diQC) is an external proficiency testing program at present
involving around 600 pathology laboratories worldwide.
Since 2003 NordiQC has assessed the performance of ER
IHC assays twice annually. A typical test program, or
“run,” evaluates the influence of epitope retrieval proce-
dures, antibody clones and concentrations, visualization
methods and staining platforms on IHC assay performance
based on circulation of unstained serial sections of carefully
composed tissue micro array (TMA) blocks to the partic-
ipating laboratories, which are required to stain the slides
using their routine methods and return the stained slide for
central assessment. In most instances an insufficient per-
formance is because of poor sensitivity of the antibody (in
terms of binding affinity and/or dilution) giving too weak or
even false-negative results, but in some cases an antibody
clone may show immunoreactivity in tumors that are neg-
ative with other clones. As an example, one core of breast
cancer in run B15, 2013, found ER negative in reference
laboratories and 215 participating laboratories, revealed a
positive staining with clone 6F11 in 15 of 37 laboratories
(Fig. 1).4 No certain methodological explanation was found
but excessive retrieval in combination with insufficient
washing was suspected. However, ER expression that only
could be detected by clone 6F11 could not be entirely ruled
out. Since there are no other commonly available methods
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for demonstration of proteins in situ, the evaluation is
dependent on knowledge about IHC-based expression in
control tissues, which was not helpful in this particular case.
In lack of methods for detection of proteins in situ,
surrogate markers of expression could be an appropriate
solution. Messenger RNA (mRNA) coding for a protein
would be expected in cells expressing the protein. In the case
of ER there are studies confirming a correlation between
mRNA and protein measured by quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) and
IHC respectively.5,6 However, the results of qRT-PCR does
not contain any information about the distribution in the
tissue and carries a risk of contamination by normal tissue,
which limits its usefulness as a specificity control. Messenger
RNA in situ hybridization is an alternative method to
visualize gene expression in situ. The branched DNA signal
amplification technique has formed the basis of currently
used mRNA-ISH analyses. This technique utilizes multiple
probe pairs that bind to unique sequences of the target
transcript giving a high specificity in target detection.7 The
method therefore allows to substantiate or validate protein
expression at the cellular level. Only few studies have
used mRNA-ISH as a reference when comparing the
performance of different IHC assays for other proteins.8–10
The aim of the present study was to compare the specificity
of IHC assays based on different antibody clones against
ER, using mRNA-ISH as reference.
MATERIALS AND METHODS
Tissue
Archived formalin-fixed paraffin embedded (FFPE)
tumor material was selected from 56 ductal carcinomas
NST diagnosed at our department in the period January
01, 2014 to July 01, 2015. All included tissue had been
fixed for 24 to 72 hours in 10% neutral-buffered formalin
and processed according to in-house standard procedure.
On the basis of the original pathology reports, 20 ER-
negative (< 1% positive cells), 26 low to medium ex-
pressers (1% to 80% positive) and 10 high expressers (80%
to 100% positive) were chosen. Large tumors were pre-
ferred in order to get sufficient tissue and to preserve tissue
for eventual diagnostic purposes in the future. In random
order, 2 neighboring cores (diameter 2.5 mm) from each
tumor were placed separately, but with the same coor-
dinates, in 2 sets of TMAs, each containing 28 tumor cores
(4 TMAs in total). In addition to the tumor tissue, each
TMA included two cores from non-neoplastic endome-
trium and tonsil for both orientation and control pur-
poses. The TMAs were cut in serial sections of 4 μm
thickness in series of 3. The first in each series were used
for ER IHC, the second for PCK IHC and the last for
ESR1 mRNA-ISH. At least 2 series were cut from each
TMA. Additional sections (nonserial) were cut for positive
and negative controls (mRNA-ISH) from each TMA.
Immunohistochemistry
Consecutive adjacent 4 μm sections were cut and
mounted on coated slides (FLEX IHC slides K8020,
Dako). The sections were dried overnight at room tem-
perature and then stored at −20°C until staining. The slides
were dried at 60°C for 1 hour. For ER, clone SP1, and
PCK the slides were placed in the BenchMark Ultra
instrument (Ventana). The slides were deparaffinized on-
board and submitted to heat induced epitope retrieval
(HIER) in Cell Conditioning 1 for 48 minutes at 99°C.
Following endogenous peroxidase blocking, the primary
antibodies for ER (rabbit monoclonal clone SP1, Thermo
Scientific, RM-9101-S, diluted 1:100) and PCK (mouse
monoclonal clone AE1/AE3, Dako M3515, diluted 1:150)
were applied for 32 minutes at 36°C. After a wash in buffer
the visualization system, OptiView DAB (HRP-labeled
FIGURE 1. Different IHC ER expression in serial sections of breast cancer as found in the NordiQC assessment scheme, run B15/
2013. A, ER negative tumor. No nuclear staining reaction of the tumor cells was found in any of 225 submitted stains based on the
mAb clone 1D5 or the rmAb clones EP1 and SP1. B, Same tumor area as in A showing diffuse, weak to moderate nuclear ER staining
reaction, considered to be false positive, which was confirmed by ESR1 mRNA-ISH, score=0. This staining pattern was obtained in
15 of 37 submitted stains based on the mAb clone 6F11.
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multimer, Ventana, 760-700) was then applied and after
a wash in the buffer the slides were finally developed
with DAB (Ventana, 760-700) and counterstained with
hematoxylin II (Ventana, 790-2208).
For ER, clone 6F11, the slides were placed in the
Omnis instrument (Dako). The slides were deparaffinized
on-board and submitted to HIER in Target Retrieval
Solution High pH for 30 minutes at 97°C. Following en-
dogenous peroxidase blocking, the primary antibody for
ER (mouse monoclonal clone 6F11, Leica, NCL-L-ER-
6F11, diluted 1:25) was applied for 20 minutes at 32°C.
After a wash in buffer the visualization system, FLEX+
mouse (HRP-labeled polymer, Dako, GV800/GV821/
DM842) was applied and after a wash in the buffer the
slides were finally developed with DAB (Dako, GV800/
GV825) and counterstained with hematoxylin (Dako,
GC808).
In Situ Hybridization
For mRNA ISH analyses, we prepared 4 µm paraffin
sections from the TMA samples. RNAscope ISH was
performed using the RNAscopeVS 2.5 Brown kit (ACD,
Newark, CA) applied to a Ventana Discovery Ultra in-
strument (Roche, Basel, Switzerland), in which all steps in
the RNAscope procedure was performed, including de-
paraffination, mRNA demasking, in situ hybridization,
probe detection, DAB-chromogen development and hem-
atoxylin counterstaining. Probes included ER mRNA
(ESR1 transcript 4, target region 677-3065, Cat #310309),
and the reference probes PPIB (positive control probe, Cat
#313909) and dapB (negative control probe, Cat #310039).
All steps in the Ventana instrument were performed ac-
cording to the standard procedure.11 Here, both demasking
steps was performed for 16 minutes and the AMP-5 step for
60 minutes for the positive and negative controls and
120 minutes for ESR1.
To test the impact of the fixation time on the
mRNA-ISH signals we used a TMA that had been pro-
duced for another study. The TMA included 3 cores from
each of 6 different non-neoplastic tissues that had been
fixed in neutral-buffered 10% formalin for 6, 24, and
72 hours respectively. mRNA-ISH was performed with
probes against the housekeeping gene PPIB and the
bacterial gene dapB, which served as a negative control.
By comparing the expression of PPIB mRNA we found
almost equal results for 24 and 72 hours fixation with
consistently stronger signals compared with the tissues
fixed for 6 hours.
Digital Image Analysis (DIA)
All slides were scanned using a Hamamatsu Nano-
zoomer HT slide scanner. The IHC slides were scanned at
×200 magnification, whereas the mRNA-ISH slides were
scanned at ×400 magnification. The scanned images were
analyzed using the VIS software platform (Visiopharm). ER
(IHC) expression in each core was measured using the
commercial applications, PCK VDS and ER APP, from
Visiopharm. Using a virtual double staining (VDS) appli-
cation, the PCK positive areas was transferred to the image
of the neighboring ER section, serving as a region of interest
(ROI) for the image analysis. The data output of the ER
APP are total number of nuclei, numbers of low, medium
and high intensity nuclei and an calculated H-score (0 to 300;
the sum of percentages of nuclei with low, medium and high
staining intensity, multiplied by 1, 2, and 3, respectively). In
addition, we developed a new ISH Application Protocol
Package (APP) for VIS (named ISH APP), which was able
to detect brown dots in the scanned images of the tumor
cores. The PCK VDS app was used to define the ROI (ep-
ithelial cells). The output of the ISH APP was the total dot
area in the ROIs of each core. The number of epithelial cells
in each ROI was then estimated by using the total number of
epithelial cells in the ROI that were detected by the ER APP
on another slide in the same series. The average dot area per
epithelial cell could then be calculated.
Tissue cores were excluded from analysis in case of
missing tissue, folded tissue, too weak hematoxylin
counterstain or too few epithelial cells in the tissue. In the
case of failed PCK-stained core sections, the correspond-
ing ER IHC and ISH cores in the series were excluded
from DIA.
Manual Scoring of mRNA-ISH
In addition to DIA the ESR1 ISH stained slides were
scored manually using a bright field microscope. We used
a modified version of the scoring algorithm provided by
the manufacturer (Advanced Cell Diagnostics).12 A subset
of tumor cores were impossible to categorize with the
original scoring algorithm and an additional category was
included in the modified version (see Table 1). The ESR1
stained slides of the tumor TMAs were scored by a single
observer (SHP), who was blinded to the results of ER
IHC.
Statistical Analysis
Reported values are averages of the available results
for each tumor. In most instances there was four of each
TABLE 1. Manual ISH Scoring Algorithm
Original ISH Score Microscope Objective Scoring (Discount Cells With Artificially High Nuclear Background Staining) Modified ISH Score
0 No staining, or <1 dot/10 cells (×40 magnification) 0
NA ≥ 1 dot/10 cells and <1 dot/cell (×40 magnification) 1
1 1-3 dots/cell (×20-40 magnification) 2
2 4-10 dots/cell, very few dot clusters (×20-40 magnification) 3
3 > 10 dots/cell, dot clusters in <10% of positive cells (×20 magnification) 4
4 > 10 dots/cell, dot clusters in ≥ 10% of positive cells (×20 magnification) 5
The scoring system provided by the manufacturer (Advanced Cell Diagnostics) was modified to include the category “≥ 1 dot/10 cells and <1 dot/cell”.
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observation per tumor (2 slides from 2 cores), but some
tumors were only represented by 2 or 3 observations, be-
cause of excluded cores. Statistics was performed using
Stata 15 (StataCorp). Correlation between H-score and
average dot area per cell was determined by linear re-
gression following a log-transformation of both datasets.
FIGURE 2. Corresponding pairs of photomicrographs with increasing ISH and IHC positivity. Left column: Examples of tissue cores
with increasing manual ESR1 mRNA-ISH scores. A: 0, B: 1, C: 2, D: 3, E: 4, F: 5. Right column: ER IHC (clone SP1) staining of the
same tissue cores assessed using H-score. A: 0, B: 4, C: 15, D: 57, E: 258, F: 292.
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A nonparametric trend-test was used to test the correla-
tion between H-score and manual ISH score.
RESULTS
In the present study, one of the 56 tumors was not
represented in the relevant cores and was excluded from
analysis. All the remaining tumors showed a moderate to
high expression of PPIB (housekeeping gene) in the epi-
thelial cells, showing that the mRNA was sufficiently
preserved for analysis. Examples of corresponding IHC
and mRNA-ISH are shown in Figure 2.
Digital Image Analysis: We found a nonlinear cor-
relation between ESR1 average dot area per cell (mRNA-
ISH) and H-score (ER IHC), with R2-values of 0.80 and
0.78 for the clones SP1 and 6F11 respectively (Fig. 3). For
high values of average dot area per cell the curves reaches a
plateau because of the upper limit of the H-score.
Manual ISH scoring: comparison of the manual ISH
scores (ESR1 mRNA-ISH) and H-scores (ER IHC) re-
sulted in significant correlation for both antibody clones,
SP1 (P< 0.001) and 6F11 (P< 0.001). Comparisons of
manual mRNA-ISH scoring categories and IHC H-scores
are shown in Table 2 and Figure 4. After review of the
slides, the outliers for the manual ISH scores of 1 and 2
was identified as borderline cases between score 1 and 2,
and 2 and 3, respectively. Seven cases with 1% to 15% ER
ICH positive nuclei, had a manual mRNA-ISH score of 2
or 3. The earlier mentioned case, with discordant positive
IHC reaction with 6F11 and negative with the 3 other
antibody clones applied, indicating a nonspecific 6F11
staining (Fig. 1), had a manual ISH score of 0, but an
H-score of 96.
DISCUSSION
For mRNA-ISH to be a useful reference marker in
the sensitivity and specificity analysis of antibodies used in
IHC, a certain level of correlation between the mRNA
and protein should be demonstrated, which was the case in
our study. Regarding the technical sensitivity of mRNA-
ISH, we observed 7 cases with ESR1 mRNA-ISH dots in
almost every tumor cell (manual ISH score 2-3), whereas
the corresponding ER IHC only showed positive staining
in a small proportion of the tumor cells (1% to 15%),
regardless of the antibody clone. Simply, the ER ex-
pression in the other tumor cells was below the lower level
of detection for IHC. This finding may help to explain
why some patients respond to antiestrogen treatment de-
spite low proportions of ER positive tumor cells.2 We did
not find any cases with a higher proportion of positive
cells by IHC than mRNA-ISH.
To our knowledge, only 2 other studies have com-
pared ESR1 mRNA-ISH and ER IHC. Bordeaux and
colleagues used the RNAscope technology and described
ESR1 mRNA-ISH as a possible predictive marker of re-
sponse to antiestrogen treatment. They reported a non-
linear correlation between ESR1 mRNA-ISH and ER
IHC, both measured by quantitative digital image analysis
(AQUA method).13 The authors reported large variations
in ER protein content in the cases with low levels of
mRNA, but did not specify the extent of protein positive,
mRNA negative cases, and their cut-off value of mRNA
positivity was defined as a certain level of fluorescence
FIGURE 3. Digital image analysis of mRNA-ISH assay. Relationship between average dot area per cell (mRNA-ISH) and H-score
(IHC). The data are log-transformed before linear regression. A, ER antibody clone SP1. B, ER antibody clone 6F11.
TABLE 2. Comparison of the Results of mRNA-ISH and IHC
ER IHC* [Mean (Range)]
Manual ISH
Score
Proportion of Positive
Tumor Cells H-score No. Cases
0 2% (0-8) 2 (0-9) 14
1 14% (1-62) 22 (1-101) 9
2 16% (1-60) 25 (1-115) 10
3 41% (2-89) 67 (2-179) 7
4 83% (61-95) 198 (127-265) 4
5 90% (47-98) 249 (104-290) 11
For definition of manual ISH score, see Table 1.
*Pooled results of SP1 and 6F11.
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intensity, preventing a direct comparison of their results
with ours. Yu et al14 investigated ESR1 mRNA-ISH also
by RNAscope technology as a complementary method to
IHC in the evaluation of ER status in breast cancers. They
used the original mRNA-ISH manual scoring algorithm
provided by ACD, considering a score ≥ 1 as positive. In
agreement with our observations, they found mRNA-ISH
to be more sensitive than IHC. Taken together, the ER
mRNA ISH method is likely to be suitable for evaluation
and specificity analysis in IHC.
In our study, we obtained the ER mRNA ISH ex-
pression levels by manual scoring, whereas the IHC scores
were obtained by digital image analysis to provide
H-scores. The choice of scoring systems gives some issues
to consider. H-score has been used for decades as a sem-
iquantitative measure of bright field IHC staining in-
tensity, and provides information about the ratio of
positive cells and staining intensity of the individual
cells.15 In routine diagnostics a cut-off level of H-score ≥ 1
(1% weakly stained nuclei) is used, whereas the manual
ISH score uses a cut-off value of ≥ 10% weakly stained
cells. Thus, the terms positive and negative are not directly
comparable between the methods. The manual ISH score
is based on the average staining intensity (number of dots)
and can be problematic with tumor heterogeneity, which is
taken into account with the IHC H-score. For DIA of
mRNA-ISH average dot area per cell was chosen as a
measure of staining intensity. This provides a continuous
scale and takes the dot clusters of the high expressing tu-
mors into account. Unfortunately, this measure does not
give information about the ratio of positive cells. More
sophisticated software is needed to provide such measures.
Many biological factors can influence the relationship
between measured mRNA and protein, including different
stability and half-life of the respective molecules.16,17 Studies
using imaging mass spectrometry and mRNA-ISH has
shown both intratumoral and intertumoral variation of
the mRNA/protein ratio of other biomarkers, and this is
probably also the case with ER.18
Despite the mentioned sources of variability, our
results support that mRNA-ISH can be used in the eval-
uation of the specificity of immunohistochemical assays
against ER. We have shown an example with suspected
nonspecific staining by assays based on the clone 6F11,
which was confirmed by mRNA-ISH. If the method can
be used in the evaluation of assays against other targets, it
would be a valuable tool in the quality assurance of im-
munohistochemistry in general.
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